A Phase II Trial of Pan-Kir2d Blockade With IPH2101 in Smoldering Multiple Myeloma

Haematologica - Italy
doi 10.3324/haematol.2013.103085
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Checkpoint Inhibition of KIR2D With the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients With Myeloma

Clinical Cancer Research
Cancer ResearchOncology
2016English

A Phase I Trial of Flavopiridol in Relapsed Multiple Myeloma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective

Oncologist
Cancer ResearchMedicineOncology
2016English

Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Hematology/Oncology Clinics of North America
OncologyHematology
2007English

Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2010English

Smoldering Multiple Myeloma: Prevalence and Current Evidence Guiding Treatment Decisions

Blood and Lymphatic Cancer: Targets and Therapy
2018English

Case Study: An Unusual Presentation of Smoldering Multiple Myeloma in a Patient With End Stage Renal Disease

American Society for Clinical Laboratory Science
2019English

Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib

Blood Cancer Journal
OncologyHematology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy